5 Medical Devices Stocks to Buy Now

by Portfolio Grader | August 6, 2012 12:00 pm

This week, five Medical Devices stocks are improving their overall ratings on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

C.R. Bard (NYSE:BCR[2]) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. C. R. Bard is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. In Portfolio Grader’s specific subcategories of Earnings Momentum and Equity, BCR also gets A’s. For more information, get Portfolio Grader’s complete analysis of BCR stock[3].

This week, Covidien (NYSE:COV[4]) pushes up from a C to a B rating. Covidien is engaged in the development, manufacture, and sale of healthcare products, including pharmaceuticals and medical supplies, for use in clinical and home settings. For more information, get Portfolio Grader’s complete analysis of COV stock[5].

This week, Medtronic Inc.‘s (NYSE:MDT[6]) ratings are up from a C last week to a B. Medtronic develops therapeutic and diagnostic medical products. For more information, get Portfolio Grader’s complete analysis of MDT stock[7].

The rating of China Kanghui (NYSE:KH[8]) moves up this week, rising from a C to a B. China Kanghui produces trauma supplies including nails, plates and screws, and cranial maxillofacial plate and screw systems, and spinal products including screws, meshes, interbody cages, and fixation systems. Shares of KH have increased 13.2% over the past month, better than the 2.7% increase the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of KH stock[9].

Novadaq Technologies (NASDAQ:NVDQ[10]) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Novadaq Technologies develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular and opthalmic diseases and conditions. For more information, get Portfolio Grader’s complete analysis of NVDQ stock[11].

Louis Navellier’s proprietary Portfolio Grader[12] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[13].

Source URL: https://investorplace.com/2012/08/5-medical-devices-stocks-to-buy-now-bcr-cov-mdt-2/

---